3D Systems Corporation
DDD · Technology
$3.29
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
Why Is 3D Systems (DDD) Down 7.6% Since Last Earnings Report?
3D Systems (DDD) reported Q2 2026 earnings that beat consensus estimates with a narrower loss of 4 cents per share versus 6 cents year-ago. Revenues of $94.6M slightly exceeded expectations, driven by double-digit growth in metal and polymer printer systems. Healthcare Solutions became the largest segment with 6.8% growth, while Industrial Solutions declined 6.7%. Gross margins contracted 170 bps due to printer sales mix and pricing pressures. The company issued Q3 guidance of $96-99M in revenues and projects continued momentum from new printer launches.
Correction: Bioprinting Market to Reach $5.1 Billion by 2030, Driven by Regenerative Medicine Demand and AI Integration
The global bioprinting market is projected to grow from $2.1 billion in 2024 to $5.1 billion by 2030 at a 16.1% CAGR, driven by regenerative medicine demand, pharmaceutical adoption for drug discovery, reduced animal testing, and AI integration. North America leads with 38% market share, while emerging technologies like 4D bioprinting and organ-on-chip devices expand market boundaries.
AI-Driven Bioprinting Emerges as a High-Conviction Investment Theme as Corporate AI Spending Surpasses $252 Billion
AI investment in bioprinting has reached a historic inflection point with corporate AI spending totaling $252.3 billion in 2024. The U.S. leads global AI investment with $109.1 billion, enabling faster commercialization of AI-integrated bioprinting technologies. Major venture capital rounds validate the sector, with companies developing AI-powered tissue therapies for drug discovery, regenerative medicine, and personalized treatments. The competitive landscape is intensifying with key players securing significant funding and strategic pharma partnerships.